Dyne Therapeutics Inc
DYN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.87B
Close$
$6.80
71.4% downside
Current Fair Value
71.4% downsideOvervalued by 71.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.87 Billion |
|---|---|
| Enterprise Value | $3.14 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | 1.06 |
| Outstanding Shares | 165,036,604 |
Return
| Return on Equity | -52.22% |
|---|---|
| Return on Assets | -41.83% |
| Return on Invested Capital | -44.45% |
Valuation & Multiples
| P/E Ratio | -7.27 |
|---|---|
| PEG | -152.75 |
| Price to Sales | - |
| Price to Book Ratio | 4.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.86 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 27, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 624.74% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.31%▼ 145.93% |
|---|---|
| Total Invested | $11.53M▼ 99.66% |
| Investors Holding | 7▼ 228.00% |
ESG Score
No data
About Dyne Therapeutics Inc
47 employeesDyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.